Table 1.
Baseline characteristics of five patients with R/R ALL.
| A | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Age | Sex | Ph + ALL | Prior lines | Prior allo-HSCT | Prior CAR-T times | Efficacy of CAR-T | Leukemia cells in BM (%) | CD19 expression (%) | Neutrophil (×106/L) | Haemoglobin (g/L) | Platelets (×106/L) | CD3+ (%) | CD3+CD8+ (%) | CD3+CD4+ (%) |
| Pt 1 | 68 | Male | No | 3 | No | 1 time | CR | 82.5 | 73.09 | 2.2 | 101 | 102 | 81 | 42 | 38 |
| Pt 2 | 31 | Male | No | 5 | No | 1 time | NR | 98.2 | 99.44 | 1.1 | 67 | 58 | 90 | 51 | 37 |
| Pt 3 | 25 | Male | No | 4 | No | 3 times | NR | 47.2 | 45.24 | 2.8 | 123 | 123 | 88 | 45 | 42 |
| Pt 4 | 48 | Female | No | 4 | No | 2 times | NR | 22.9 | 59.03 | 1.5 | 117 | 152 | 92 | 39 | 50 |
| Pt 5 | 20 | Male | No | 5 | Yes | 2 times | NR | 54.0 | 32.02 | 1.2 | 86 | 82 | 73 | 25 | 46 |
| B |
|||||||||||||||
| Characteristics | n = 5 | ||||||||||||||
| Age, year | 20–68 | ||||||||||||||
| Sex, male/female | 4/1 | ||||||||||||||
| Ph+ ALL, yes/no | 0/5 | ||||||||||||||
| Prior lines (Including CAR-T) | 3–5 | ||||||||||||||
| Prior allo-HSCT, yes/no | ¼ | ||||||||||||||
| Prior CAR-T times | 1–3 | ||||||||||||||
| Efficacy of last CAR-T, CR/NR | ¼ | ||||||||||||||
| Time of CAR-T to Blinatumomab, months | 1–18 | ||||||||||||||
| Leukemia cells in BM (%) | 22.9–98.2 | ||||||||||||||
| CD19 expression in Leukemia cells (%) | 32.02–99.44 | ||||||||||||||
| Neutrophil (×106/L) | 1.1–2.8 | ||||||||||||||
| Haemoglobin (g/L) | 67–123 | ||||||||||||||
| Platelets (×106/L) | 58–152 | ||||||||||||||
| CD3+ (%) | 73–92 | ||||||||||||||
| CD3+CD8+ (%) | 25–51 | ||||||||||||||
| CD3+CD4+ (%) | 32–50 | ||||||||||||||
Ph+ ALL: Philadelphia chromosome-positive ALL; allo-HSCT: Allogenic hematopoietic stem cell transplantation; CD3+: CD3+ T cells in peripheral blood; CD3+CD8+: CD3+CD8+ T cells in peripheral blood; CD3+CD4+: CD3+CD4+ T cells in peripheral blood